Status:

COMPLETED

Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma

Lead Sponsor:

Massachusetts General Hospital

Collaborating Sponsors:

Dana-Farber Cancer Institute

Beth Israel Deaconess Medical Center

Conditions:

Hepatocellular Carcinoma

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The purpose of this study is to test the safety of bevacizumab when given in combination with gemcitabine and oxaliplatin and to see what effects (good or bad) it has on patients with hepatocellular c...

Detailed Description

* Treatment is given in cycles, each cycle (except for cycle 1) is 4 weeks long. Cycle 1 is only 2 weeks long. * During cycle one only, bevacizumab will be given intravenously on day one. Two weeks af...

Eligibility Criteria

Inclusion

  • Unresectable or metastatic hepatocellular carcinoma
  • Measurable tumors
  • Adequate hepatic function: total bilirubin \< 3.0mg/dl; AST \< 7x ULN
  • Adequate bone marrow function: ANC \> 1,000/mm3; platelets \> 75,000/mm3
  • INR \< 1.5 for those who are not on anticoagulation
  • Up to two prior chemotherapy regimens for hepatocellular carcinoma
  • 18 years of age or older
  • ECOG performance status of 0-1
  • Life expectancy of \> 12 weeks

Exclusion

  • Clinically apparent central nervous system metastases or carcinomatous meningitis
  • Uncontrolled serious medical or psychiatric illness
  • Pregnant or lactating women
  • Current or recent (within 4 weeks of first study infusion) participation in experimental study drug
  • Uncontrolled hypertension
  • Significant proteinuria
  • Serious, non-healing wound, ulcer, or bone fracture
  • Evidence of bleeding diathesis or coagulopathy

Key Trial Info

Start Date :

April 1 2004

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2011

Estimated Enrollment :

33 Patients enrolled

Trial Details

Trial ID

NCT00142467

Start Date

April 1 2004

End Date

June 1 2011

Last Update

March 18 2014

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

2

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States, 02115

3

Dana-Farber Cancer Institute

Boston, Massachusetts, United States, 02115

Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma | DecenTrialz